Postaus
Happy_shanky
🚨 $LLY — ELI LILLY’S NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLY’S EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
⚠️ HOWEVER, 11%–27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Vastuuvapauslauseke: OKX Orbit -sisältö on tarkoitettu ainoastaan tiedotustarkoituksiin. Lisätietoja
Vastaukset
Ei vielä kommentteja. Ole ensimmäinen vastaaja!
Tämän päivän markkinakohina
1#USJobsDataToday
Suosittu
2#USIranOilTensions
3#BTCInflowETHOutflow
